Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Polycystic Ovary SyndromeObstructive Sleep Apnea
Interventions
DRUG

Depot Lupron followed by estrogen plus placebo

A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.

Trial Locations (1)

60637

University of Chicago Department of Medicine, Section of Endocrinology, Diabetes & Metabolism, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Chicago

OTHER